Bevifimod

Names

[ CAS No. ]:
2223113-32-2

[ Name ]:
Bevifimod

Biological Activity

[Description]:

Bevifimod (PRTX-100) is a highly purified form of Staphylococcal protein A (SpA). Bevifimod can be used for idiopathic thrombocytopenic purpura (ITP) research[1][2].

[Related Catalog]:

Research Areas >> Cardiovascular Disease
Signaling Pathways >> Others >> Others
Research Areas >> Inflammation/Immunology

[In Vitro]

Bevifimod（PRTX-100；250、25 和 2.5 ng/mL；48 小时）抑制外周血单核细胞 (PBMC) 中人单核细胞对 W632 调理血小板的吞噬作用[1]。

[In Vivo]

Bevifimod (PRTX-100; 2.5-250 μg/kg; i.v.; once every two weeks; for 4 weeks) increases platelet counts to within normal levels within 1-2 weeks and none of the mice died[2]. Animal Model: SCID mice bearing immune thrombocytopenia (ITP)[2] Dosage: 2.5 μg/kg, 25 μg/kg, 250 μg/kg Administration: i.v.; once every two weeks; for 4 weeks Result: Raised platelet counts in a well-established murine model of ITP.

[References]

[1]. ChrisYatkoBS, et al. PRTX-100 Inhibits Platelet Phagocytosis In Vitro. Blood (2006) 108 (11): 1081.

[2]. John W. Semple, et al. Successful Treatment of Thrombocytopenia with Staphylococcal Protein A (PRTX-100) in a Murine Model of Immune Thrombocytopenia (ITP). Blood (2015) 126 (23): 1045.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.